NFL Biosciences

ALNFLFR0014003XT0

Filings

71 filings

All Inside information62 Share buyback3 Annual financial report2 Earnings release2 AGM documents1 Half-year financial report1

28/07/2026
Inside Information / Other news releases
Inside informationFR
07/07/2026
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Share buybackFrench
07/07/2026
Inside Information / Other news releases
Inside informationFR
30/06/2026
Inside Information / Other news releases
Inside informationFR
17/06/2026
Informations privilégiées / Autres communiqués
Inside informationFrench
01/06/2026
Modalités de mise à disposition des documents préparatoires à l'AG
AGM documentsFrench
01/06/2026
Inside Information / Other news releases
Inside informationFR
25/05/2026
Inside Information / Other news releases
Inside informationFR
11/05/2026
Inside Information / Other news releases
Inside informationFR
04/05/2026
Inside Information / Other news releases
Inside informationFR
27/04/2026
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Annual financial reportFrench
15/04/2026
Inside Information / News release on accounts, results
Inside informationFR
15/04/2026
Inside Information / Other news releases
Inside informationFR
07/04/2026
Inside Information / Other news releases
Inside informationFR
11/03/2026
Inside Information / Other news releases
Inside informationFR
19/02/2026
Inside Information / Other news releases
Inside informationFR
26/01/2026
Inside Information / Other news releases
Inside informationFR
06/01/2026
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Share buybackFrench
08/12/2025
Inside Information / Other news releases
Inside informationFR
12/11/2025
Inside Information / Other news releases
Inside informationFR
20/10/2025
Inside Information / Other news releases
Inside informationFR
17/10/2025
Rapports financiers et d'audit semestriels/examens réduits / Modalités de mise à disposition du rapport financier semestriel
Half-year financial reportFrench
16/10/2025
Inside Information / News release on accounts, results
Inside informationFR
01/09/2025
Inside Information / Other news releases
Inside informationFR
28/07/2025
Inside Information / Other news releases
Inside informationFR
22/07/2025
Inside Information / Other news releases
Inside informationFR
03/07/2025
NFL Biosciences strengthens its clinical leadership by expanding Dr. Yannick Plétan’s role as Chief Medical Officer as part of the acceleration of its clinical development program for NFL-101 in smoking cessation
Inside informationFR
02/07/2025
Bilan semestriel du contrat de liquidité
Share buybackFrench
23/05/2025
NFL Biosciences announces the success of its capital increase capped at €3 million
Inside informationFR
22/05/2025
NFL Biosciences launches a capital increase of approximately €2.2 million
Inside informationFR
21/05/2025
NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025
Inside informationFrench
12/05/2025
Marex Group initie à l’achat la couverture de NFL Biosciences
Inside informationFrench
12/05/2025
NFL Biosciences strengthens its scientific committee with world-class experts to support the Phase 3 development of NFL-101, its first-in-class therapy for tobacco addiction
Inside informationFR
06/05/2025
Assemblée générale mixte du 21 mai 2025 : modalités de mise à disposition et consultation des documents préparatoires
Inside informationFrench
05/05/2025
NFL Biosciences announces results from a new study conducted with the CEA providing further insight into the effects of NFL-101, its first-in-class treatment for tobacco addiction, and highlighting its prolonged activity
Inside informationFR
24/04/2025
Marex Group initiates coverage of NFL Biosciences with a Buy rating
Inside information
15/04/2025
NFL Biosciences annonce la mise à disposition de son rapport financier annuel 2024
Annual financial reportFrench
11/04/2025
NFL Biosciences presents its 2024 annual results and provides an update on its clinical program
Earnings releaseFR
24/03/2025
NFL Biosciences presents the immunological analysis results of its phase 2 CESTO II study confirming the efficacy of NFL-101, its first-in-class treatment for tobacco addiction
Inside informationFR
05/03/2025
NFL Biosciences publishes its 2025 financial agenda
Inside informationFR
04/02/2025
NFL Biosciences publishes positive results from a complementary program confirming the excellent safety profile of NFL-101, its first-in-class treatment for tobacco addiction
Inside informationFR
10/01/2025
NFL BIOSCIENCES : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ DU 2ème SEMESTRE 2024
Inside informationFrench

About

ISIN: FR0014003XT0
Ticker: ALNFL
LEI: 9695006VJWNTN4UNHA27
Country of registration: FR
Last filing: 28/07/2026, 17:45

Sparse profile

The AMF publishes neither sector nor description. These fields are enriched from Wikidata where a match exists.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive